がん生物学の世界市場2019-2023

◆英語タイトル:Global Cancer Biologics Market 2019-2023
◆商品コード:IRTNTR31171
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年4月17日
◆ページ数:127
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、がん生物学の世界市場について調査・分析し、市場概要、市場環境、がん生物学市場規模、製品別(モノクローナル抗体、ワクチン、細胞及び遺伝子治療、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・がん生物学の世界市場概要
・がん生物学の世界市場環境
・がん生物学の世界市場動向
・がん生物学の世界市場規模
・がん生物学の世界市場:業界構造分析
・がん生物学の世界市場:製品別(モノクローナル抗体、ワクチン、細胞及び遺伝子治療、その他)
・がん生物学の世界市場:地域別市場規模・分析
・がん生物学の北米市場規模・予測
・がん生物学のヨーロッパ・中東・アフリカ市場規模・予測
・がん生物学のアジア太平洋市場規模・予測
・がん生物学の主要国分析
・がん生物学の世界市場:意思決定フレームワーク
・がん生物学の世界市場:成長要因、課題
・がん生物学の世界市場:競争環境
・がん生物学の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The rising global incidences of cancer are likely to impact the market’s growth during the forecast period. Increasing prevalence of environmental factors including tobacco smoking and pollution and changing dietary patterns are expected to contribute directly to the increased global incidences of cancer. Such rising incidences of this condition will eventually contribute to the cancer biologics market growth during the forecast period. Technavio’s analysts have predicted that the cancer biologics market will register a CAGR of over 11% by 2023.

Market Overview

The rising global incidence of cancer

The major etiological factors leading to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer.

Patient expiry of major cancer biologics

The emergence of biosimilars due to patent expiration of biologics hinder the market growth, despite the increased incidence of cancer during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cancer biologics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Manufacturers in the global cancer biologics market are entering into strategic collaborations to develop or commercialize biologics indicated for the treatment of various types of cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Monoclonal antibodies – Market size and forecast 2018-2023

Vaccines – Market size and forecast 2018-2023

Cell and gene therapy – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: Monoclonal antibodies – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Monoclonal antibodies – Year-over-year growth 2019-2023 (%)

Exhibit 21: Vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 23: Cell and gene therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Cell and gene therapy – Year-over-year growth 2019-2023 (%)

Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Others – Year-over-year growth 2019-2023 (%)

Exhibit 27: Market opportunity by product

Exhibit 28: Customer landscape

Exhibit 29: Market share by geography 2018-2023 (%)

Exhibit 30: Geographic comparison

Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: North America – Year-over-year growth 2019-2023 (%)

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Key leading countries

Exhibit 40: Market opportunity

Exhibit 41: Biologics in the pipeline for cancer

Exhibit 42: List of recently approved cancer biologics by the FDA

Exhibit 43: Cancer biologics and their biosimilar versions

Exhibit 44: Impact of drivers and challenges

Exhibit 45: List of collaborations between manufacturers of cancer biologics

Exhibit 46: List of predictive biomarkers for cancer

Exhibit 47: Vendor landscape

Exhibit 48: Landscape disruption

Exhibit 49: Vendors covered

Exhibit 50: Vendor classification

Exhibit 51: Market positioning of vendors

Exhibit 52: Amgen Inc. – Vendor overview

Exhibit 53: Amgen Inc. – Business segments

Exhibit 54: Amgen Inc. – Organizational developments

Exhibit 55: Amgen Inc. – Geographic focus

Exhibit 56: Amgen Inc. – Key offerings

Exhibit 57: Bristol-Myers Squibb Company – Vendor overview

Exhibit 58: Bristol-Myers Squibb Company – Business segments

Exhibit 59: Bristol-Myers Squibb Company – Organizational developments

Exhibit 60: Bristol-Myers Squibb Company – Geographic focus

Exhibit 61: Bristol-Myers Squibb Company – Key offerings

Exhibit 62: Eli Lilly and Company – Vendor overview

Exhibit 63: Eli Lilly and Company – Business segments

Exhibit 64: Eli Lilly and Company – Organizational developments

Exhibit 65: Eli Lilly and Company – Geographic focus

Exhibit 66: Eli Lilly and Company – Segment focus

Exhibit 67: Eli Lilly and Company – Key offerings

Exhibit 68: F. Hoffmann-La Roche Ltd – Vendor overview

Exhibit 69: F. Hoffmann-La Roche Ltd – Business segments

Exhibit 70: F. Hoffmann-La Roche Ltd – Organizational developments

Exhibit 71: F. Hoffmann-La Roche Ltd – Geographic focus

Exhibit 72: F. Hoffmann-La Roche Ltd – Segment focus

Exhibit 73: F. Hoffmann-La Roche Ltd – Key offerings

Exhibit 74: Merck & Co., Inc. – Vendor overview

Exhibit 75: Merck & Co., Inc. – Business segments

Exhibit 76: Merck & Co., Inc. – Organizational developments

Exhibit 77: Merck & Co., Inc. – Geographic focus

Exhibit 78: Merck & Co., Inc. – Segment focus

Exhibit 79: Merck & Co., Inc. – Key offerings

Exhibit 80: Validation techniques employed for market sizing



【掲載企業】

Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[がん生物学の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆